医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New Partnership with Meyra Extends Aesynt’s IV Robotics Footprint to the Republics of Azerbaijan and Turkey

2015年03月03日 AM02:30
このエントリーをはてなブックマークに追加


 

CRANBERRY TOWNSHIP, Pa.

Aesynt, a leading provider of integrated pharmacy automation solutions for hospitals and health systems, today announced a new strategic partnership with Meyra to market robotic solutions for public hospitals’ sterile compounding in the Republics of Azerbaijan and Turkey.

Supporting safety in the sterile compounding process is important to the Republic of Turkey’s Ministry of Health, as evidenced by the recent unprecedented step to establish reimbursement for public hospitals that use IV robotics for chemotherapy sterile compounding at a rate of 120 Turkish Lira per patient dose (approximately $48 USD).

“The Ministry has realized the benefits of Aesynt’s IV automation oncology solutions since 2008 with over 20 units of Aesynt’s first-generation chemotherapy robot (CytoCare), and is now ready to upgrade to i.v.STATION ONCO, Aesynt’s second-generation, state-of-the-art oncology robot,” explained Akif Uzuncarsili, General Manager of Meyra. “We are very pleased to be able to offer Aesynt’s global leading robotic solutions to help our customers automate compounding processes to enhance workflow and reduce errors while improving safety in the production of IV admixtures, including its market-leading upgrades such as tamper-evident capping, automatic labeling, decreased size and weight, and increased speed/throughput.”

Aesynt’s robotic solutions, including i.v.STATIONTM, i.v.STATION ONCOTM and i.v.STATIONTM 2 for total parenteral nutrition (TPN) preparations, are designed to automate the sterile compounding of IV admixtures, helping hospitals to:

  • Support safe and efficient production of ready-to-administer IVs;
  • Reduce medication errors;
  • Increase medication throughput; and
  • Lower costs associated with IV compounding and dispensing.

“The manual compounding and dispensing of injectable medications is one of the highest risk, expensive and labor-intensive processes in the hospital pharmacy,” said Kraig McEwen, CEO of Aesynt. “Through our new partnership with Meyra, we are able to extend the safety, flexibility and cost benefits of IV automation to public healthcare systems in Turkey and Azerbaijan.”

Aesynt is the only company to offer automation solutions at every stage of medication delivery—from the medication distribution source to administration at the patient bedside—regardless of medication type or distribution model.

About Meyra

Meyra, located in Izmir, Turkey, was founded in 2010 and has rapidly grown to operate 18 sterile compounding centers at many prestigious university hospitals in Turkey such as Haccetteppe, Ege and Dokuzeylul, amongst others. Meyra currently covers 40% of the Turkish TPN market. Learn more by visiting http://www.meyrasaglik.com.tr.

About Aesynt

Aesynt is committed to continuously advancing medication management, offering integrated pharmacy automation solutions that help health systems to support improved patient outcomes, build stronger businesses and manage ongoing change. For more information, visit www.aesynt.com. Follow Aesynt on Twitter at https://twitter.com/aesynt.

CONTACT

Dodge Communications
Taylor Davis, 770-576-3195
tdavis@dodgecommunications.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease